BRAIN and NERVE－神経研究の進歩76巻4号

2024年04月発行

総説

アルツハイマー病におけるアミロイドβの役割—最新の知見を踏まえて

著者： 小野賢二郎¹ 椎名浩子² 松本麻莉子² 中村陽介²

所属機関： ¹金沢大学医薬保健研究域医学系脳神経内科学 ²エーザイ株式会社メディカル本部

ページ範囲：P.399 - P.408

文献概要

アミロイド前駆体蛋白からアミロイドβ（amyloid β：Aβ）が切り出され，Aβの異常凝集・沈着により神経変性を引き起こす「アミロイドカスケード仮説」は1992年に提唱された。近年では，Aβの凝集過程において，中間凝集体であるオリゴマーやプロトフィブリルの有する神経毒性（オリゴマー仮説）が注目を集めている。この中間凝集体を主なターゲットとする抗Aβプロトフィブリル抗体薬も開発され，新たなアルツハイマー病治療が期待される。
＊本論文中に掲載されている二次元コード部分をクリックすると，関連する動画を視聴することができます（公開期間：2027年4月30日まで公開）。

参考文献

1）2022 Alzheimer's disease facts and figures. Alzheimers Dement 18: 700-789, 2022

2）二宮利治: 厚生労働科学研究費補助金, 厚生労働科学特別研究事業 日本における認知症の高齢者人口の将来推計に関する研究 平成26年度総括研究報告書. 2015

3）河野禎之, 木之下節夫, 神戸泰紀, 木之下徹: 厚生労働科学研究費補助金（認知症対策総合研究事業）分担研究報告書「病・診・介護の連携による認知症ケアネットワーク構築に関する研究事業」我が国と世界における認知症及びMCI有病率に関するシミュレータの作成. 2013

4）厚生労働省: 認知症施策推進総合戦略（新オレンジプラン）: 認知症高齢者等にやさしい地域づくりに向けて. 2017

5）厚生労働省認知症施策推進関係閣僚会議: 認知症施策推進大綱. 2019

6）令和五年法律第六十五号 共生社会の実現を推進するための認知症基本法. 2023　https://elaws.e-gov.go.jp/document?lawid=505AC1000000065（最終閲覧日: 2024年3月12日）

7）日本神経学会（監修）, 「認知症疾患診療ガイドライン」作成委員会（編）: 認知症疾患診療ガイドライン2017. 第3章 治療. 医学書院, 東京, 2017

8）Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, et al: Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement (N Y) 8: e12295, 2022［doi: 10.1002/trc2.12295］

9）Maurer K, Volk S, Gerbaldo H: Auguste D and Alzheimer's disease. Lancet 349: 1546-1549, 1997

10）Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185, 1992

11）Beyreuther K, Masters CL: Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer's disease: precursor-product relationships in the derangement of neuronal function. Brain Pathol 1: 241-251, 1991

12）Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-388, 1991

13）Selkoe DJ: The molecular pathology of Alzheimer's disease. Neuron 6: 487-498, 1991

14）Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, et al: NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 14: 535-562, 2018

15）McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269, 2011

16）Revised Criteria for Diagnosis and Staging of Alzheimer's Disease: Alzheimer's Association Workgroup　https://aaic.alz.org/diagnostic-criteria.asp（最終閲覧日: 2024年3月12日）

17）Bekris LM, Yu CE, Bird TD, Tsuang DW: Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23: 213-227, 2010

18）AlzForum Foundation: Mutations　https://www.alzforum.org/mutations（最終閲覧日: 2024年3月12日）

19）Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, et al: The ‘Arctic’ APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 4: 887-893, 2001

20）Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Näslund J, et al: Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol 65: 499-505, 2008

21）Johansson AS, Berglind-Dehlin F, Karlsson G, Edwards K, Gellerfors P, et al: Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt. FEBS J 273: 2618-2630, 2006

22）Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, et al: A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488: 96-99, 2012

23）Querfurth HW, LaFerla FM: Alzheimer's disease. N Engl J Med 362: 329-344, 2010

24）Hampel H, Hardy J, Blennow K, Chen C, Perry G, et al: The Amyloid-β Pathway in Alzheimer's Disease. Mol Psychiatry 26: 5481-5503, 2021

25）Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, et al: Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry 75: 84-95, 2018

26）Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, et al: Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71: 362-381, 2012

27）Thal DR, Rüb U, Orantes M, Braak H: Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791-1800, 2002

28）Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, et al: A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. Brain 142: 1723-1735, 2019

29）Price JL, Morris JC: Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann Neurol 45: 358-368, 1999

30）Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, et al: Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30: 1026-1036, 2009

31）Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, et al: Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between β-amyloid and tauopathy. JAMA Neurol 73: 1070-1077, 2016

32）Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, et al; Dominantly Inherited Alzheimer Network: Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367: 795-804, 2012

33）Futamura A, Hieda S, Mori Y, Kasuga K, Sugimoto A, et al: Toxic amyloid-β42 conformer may accelerate the onset of Alzheimer's disease in the preclinical stage. J Alzheimers Dis 80: 639-646, 2021

34）Irie K: New diagnostic method for Alzheimer's disease based on the toxic conformation theory of amyloid β. Biosci Biotechnol Biochem 84: 1-16, 2020

35）Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK: Co-occurrence of Alzheimer's disease β-amyloid and tau pathologies at synapses. Neurobiol Aging 31: 1145-1152, 2010

36）Sato C, Barthélemy NR, Mawuenyega KG, Patterson BW, Gordon BA, et al: Tau kinetics in neurons and the human central nervous system. Neuron 97: 1284-1298.e7, 2018［doi: 10.1016/j.neuron.2018.02.015］

37）van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, et al: Lecanemab in early Alzheimer's disease. N Engl J Med 388: 9-21, 2023

38）Johnson K, Li D, Dhadda S, Sachdev P, Charil A, et al: Biomarker assessments from clarity AD: downstream implications of targeting protofibrils and tau as a predictive biomarker (Abstract: 16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24-27, 2023: Symposia). J Prev Alzheimers Dis 10: S10, 2023

39）Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, et al: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther 13: 80, 2021［doi: 10.1186/s13195-021-00813-8］

40）Madhu P, Mukhopadhyay S: Distinct types of amyloid-β oligomers displaying diverse neurotoxicity mechanisms in Alzheimer's disease. J Cell Biochem 122: 1594-1608, 2021

41）Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, et al: Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 38: 1205-1235, 2017

42）Ono K, Watanabe-Nakayama T: Aggregation and structure of amyloid β-protein. Neurochem Int 151: 105208, 2021［doi: 10.1016/j.neuint.2021.105208］

43）Cline EN, Bicca MA, Viola KL, Klein WL: The amyloid-β oligomer hypothesis: beginning of the third decade. J Alzheimers Dis 64: S567-S610, 2018

oligomers induce neurotoxicity via plasma membrane damage. FASEB J 33: 9220-9234, 2019

45）Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB: Amyloid beta-protein fibrillogenesis: detection of a protofibrillar intermediate. J Biol Chem 272: 22364-22372, 1997

46）Ono K, Tsuji M: Protofibrils of amyloid-β are important targets of a disease-modifying approach for Alzheimer's disease. Int J Mol Sci 21: 952, 2020［doi: 10.3390/ijms21030952］

47）Ono K: Alzheimer's disease as oligomeropathy. Neurochem Int 119: 57-70, 2018

48）Matsumura S, Shinoda K, Yamada M, Yokojima S, Inoue M, et al: Two distinct amyloid beta-protein (Abeta) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology, and toxicity analyses. J Biol Chem 286: 11555-11562, 2011

49）Velasco PT, Heffern MC, Sebollela A, Popova IA, Lacor PN, et al: Synapse-binding subpopulations of Aβ oligomers sensitive to peptide assembly blockers and scFv antibodies. ACS Chem Neurosci 3: 972-981, 2012

50）Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, et al: Quaternary structure defines a large class of amyloid-β oligomers neutralized by sequestration. Cell Rep 11: 1760-1771, 2015

51）Watanabe-Nakayama T, Ono K, Itami M, Takahashi R, Teplow DB, et al: High-speed atomic force microscopy reveals structural dynamics of amyloid β1-42 aggregates. Proc Natl Acad Sci U S A 113: 5835-5840, 2016

52）Breydo L, Kurouski D, Rasool S, Milton S, Wu JW, et al: Structural differences between amyloid beta oligomers. Biochem Biophys Res Commun 477: 700-705, 2016

53）Ono K, Condron MM, Teplow DB: Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A 106: 14745-14750, 2009

54）Hayden EY, Teplow DB: Amyloid β-protein oligomers and Alzheimer's disease. Alzheimers Res Ther 5: 60, 2013［doi: 10.1186/alzrt226］

55）Ferreira ST, Klein WL: The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem 96: 529-543, 2011

56）Masters CL, Selkoe DJ: Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2: a006262, 2012［doi: 10.1101/cshperspect.a006262］

57）Sanchez-Varo R, Sanchez-Mejias E, Fernandez-Valenzuela JJ, De Castro V, Mejias-Ortega M, et al: Plaque-associated oligomeric amyloid-beta drives early synaptotoxicity in APP/PS1 mice hippocampus: ultrastructural pathology analysis. Front Neurosci 15: 752594, 2021［doi: 10.3389/fnins.2021.752594］

58）McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, et al: Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860-866, 1999

59）Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, et al: Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155: 853-862, 1999

60）O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, et al: Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 30: 14411-14419, 2010

61）Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, et al: Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem 103: 334-345, 2007

62）Tucker S, Möller C, Tegerstedt K, Lord A, Laudon H, et al: The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis 43: 575-588, 2015

63）Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, et al: An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol Dis 36: 425-434, 2009

64）Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, et al: Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLOS ONE 7: e32014, 2012［doi: 10.1371/journal.pone.0032014］

65）Sehlin D, Hedlund M, Lord A, Englund H, Gellerfors P, et al: Heavy-chain complementarity-determining regions determine conformation selectivity of anti-aβ antibodies. Neurodegener Dis 8: 117-123, 2011

66）Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, et al: Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Alzheimers Res Ther 8: 14, 2016［doi: 10.1186/s13195-016-0181-2］

67）Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, et al: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther 13: 80, 2021［doi: 10.1186/s13195-021-00813-8］

68）Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, et al: Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for alzheimer's disease. Neurotherapeutics 20: 195-206, 2023

69）Watanabe-Nakayama T, Tsuji M, Umeda K, Oguchi T, Konno H, et al: Structural dynamics of amyloid-β protofibrils and actions of anti-amyloid-β antibodies as observed by high-speed atomic force microscopy. Nano Lett 23: 6259-6268, 2023

70）Stern AM, Yang Y, Jin S, Yamashita K, Meunier AL, et al: Abundant Aβ fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer's disease brains. Neuron 111: 2012-2020. e4, 2023［doi: 10.1016/j.neuron.2023.04.007］

71）Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, et al: Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7: 367-385, 2011

72）Barakos J, Sperling R, Salloway S, Jack C, Gass A, et al: MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol 34: 1958-1965, 2013

73）エーザイ株式会社: レケンビ®点滴静注 添付文書 第2版. 2023年12月　https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/170033_1190408A1025_1_01（最終閲覧日: 2024年3月12日）

74）厚生労働省: 最適使用推進ガイドライン: レカネマブ（遺伝子組換え）（販売名: レケンビ点滴静注200mg, レケンビ点滴静注500mg）. 2023年12月　https://www.pmda.go.jp/files/000265885.pdf（最終閲覧日: 2024年3月12日）